(HealthDay News) — There is no difference in fetal or maternal outcomes among women with preterm premature rupture of membranes who receive azithromycin instead of erythromycin, according to a study published online August 4 in Obstetrics & Gynecology.
Rebecca C. Pierson, MD, from the Indiana University School of Medicine in Indianapolis, and colleagues retrospectively studied data from women with preterm premature rupture of membranes between 24–34 completed weeks of gestation. Women were classified by those who received ampicillin and erythromycin (75 patients) and those who received ampicillin and azithromycin (93 patients).
The researchers observed no difference in latency (time from first antibiotic dose to delivery) between groups: 9.6 days (erythromycin) vs. 9.4 (azithromycin) days (P=0.40). Rates of chorioamnionitis, cesarean delivery, Apgar scores, birth weight, neonatal death, neonatal sepsis, and neonatal respiratory distress syndrome did not differ between groups.
“Among women with preterm premature rupture of membranes between 24–34 completed weeks of gestation, substitution of azithromycin for erythromycin in the recommended antibiotic regimen did not affect latency or any other measured maternal or fetal outcomes,” the authors write.